Opioid receptor interactions: Local and nonlocal, symmetric and asymmetric, physical and functional

Life Sciences

Volumn 73, Issue 15, 2003, Pages 1873-1893

  Smith, Andrew P ^a   Lee, Nancy M ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Heteromer; Homomer; Opioid receptor; Potentiation; Synergism; Tolerance

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CALCIUM; CELL SURFACE RECEPTOR; DELTA OPIATE RECEPTOR; DYNORPHIN A; DYNORPHIN[1-13]; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; LIGAND; MELANOCORTIN; METENKEPHALIN; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NORBINALTORPHIMINE; OPIATE AGONIST; OPIATE RECEPTOR; OUABAIN; PHOSPHATIDYLINOSITOL 3 KINASE; RECEPTOR SUBTYPE;

ANTINOCICEPTION; CELL INTERACTION; HUMAN; INTERNALIZATION; LIGAND BINDING; NERVE CELL; NONHUMAN; OLIGOMERIZATION; RECEPTOR BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0042243639     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00549-6     Document Type: Review

References (151)

1. Abdelhamid E.E., Takemori A.E. Characteristic of mu and delta opioid binding sites in striatal slices of morphine-tolerant and -dependent rats. European Journal of Pharmacology. 198(2-3):1991;157-163.
2. Aceto M.D., Dewey W.L., Chang J.K., Lee N.M. Dynorphin-(1-13): effects in nontolerant and morphine-dependent rhesus monkeys. European Journal of Pharmacology. 83(1-2):1982;139-142.
3. Ai W., Gong J., Yu L. MAP kinase activation by mu opioid receptor involves phosphatidylinositol 3-kinase but not the cAMP/PKA pathway. Federation of European Biological Societies Letters. 456(1):1999;196-200.
4. Angers S., Salahpour A., Bouvier M. Biochemical and biophysical demonstration of GPCR oligomerization in mammalian cells. Life Sciences. 68(19-20):2001;2243-2250.
5. Atweh S.F., Kuhar M.J. Distribution and physiological significance of opioid receptors in the brain. British Medical Bulletin. 39(1):1983;47-52.
6. Ayoub M.A., Couturier C., Lucas-Meunier E., Angers S., Fossier P., Bouvier M., Jockers R. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. Journal of Biological Chemistry. 277(24):2002;21522-21528.
7. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin activity. Annual Review of Neuroscience. 7:1984;309-338.
8. Baumeister A.A., Hawkins M.F., Anticich T.G., Moore L.L., Higgins T.D. Bilateral intranigral microinjection of morphine and opioid peptides produces antinociception in rats. Brain Research. 411(1):1987;183-186.
9. Besse D., Lombard M.C., Besson J.M. Up-regulation of [3H]DAMGO and [3H]DTLET Opioid Binding Sites in Laminae I-II ofthe Spinal Cord in Intact and Deafferented Morphine-tolerant Animals. Neuroscience Letters. 136(2):1992;209-212.
10. Bian D., Ossipov M.H., Ibrahim M., Raffa B., Tallarida R.J., Malan T.P. Jr., Lai J., Porreca F. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Research. 83(1-2):1999;55-63.
11. Bodnar R.J. Supraspinal circuitry mediating opioid antinociception: antagonist and synergy studies in multiple sites. Journal of Biomedical Science. 7(3):2000;181-194.
12. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nature Review of Neuroscience. 2(4):2001;274-286.
13. Brodsky M., Elliott K., Hyanksy A., Inturrisi C.E. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Research Bulletin. 38(2):1995;135-141.
14. Castanas E., Giraud P., Bourhim N., Cantau P., Oliver C. Kappa 3: a novel subtype of the kappa opioid site in bovine adrenal medulla, highly selective for Met-enkephalin-Arg6-Phe7. Neuropeptides. 5(1-3):1984;133-136.
15. Chen L., Gu Y., Huang L.-Y.M. The opioid peptide dynorphin directly blocks NMDA receptor channels in the rat. Journal of Physiology. 482(Pt. 3):1995;575-581.
16. Chen Y., Mestek A., Liu J., Hurley J.A., Yu L. Molecular cloning and functional expression of a m-opioid Receptor from rat brain. Molecular Pharmacology. 44(1):1993;8-12.
17. Clark J.A., Liu L., Price M., Hersh B., Edelson M., Pasternak G.W. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. Journal of Pharmacology and Experimental Therapeutics. 251(2):1989;461-468.
18. Cvejic S., Devi L.A. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. Journal of Biological Chemistry. 272(43):1997;26959-26964.
19. Davis M.E., Akera T., Brody T.M., Watson L. Opiate receptor: cooperativity of binding observed in brain slices. Proceedings of the National Academy of Sciences, USA. 74(12):1977;5764-5766.
20. Demoliou-Mason C.D., Barnard E.A. Distinct subtypes of the opioid receptor with allosteric interactions in brain membranes. Journal of Neurochemistry. 46(4):1986;1118-1128.
21. Devi L.A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends in Pharmacological Sciences. 22(10):2001;532-537.
22. Devi L.A. G-protein-coupled receptor dimers in the lime light. Trends in Pharmacological Sciences. 21(9):2000;324-326.
23. DiToro R., Campana G., Sciaretta V., Murari G., Spampinato S. Regulation of delta opioid receptors by delta9-tetrahydrocannibinol in NG108-15 hybrid cells. Life Sciences. 63(14):1998;PL197-PL204.
24. Djellas Y., Antonakis K., LeBreton G.C. A molecular mechanism for signaling between seven transmembrane receptors: evidence for a redistribution of G proteins. Proceedings of the National Academy of Sciences, USA. 95(18):1998;10944-10948.
25. Dumont M., Lemaire S. Interactions of dynorphin A and related peptides with cardiac ouabain binding sites. Journal of Molecular and Cellular Cardiology. 28(3):1996;615-621.
26. Evans C.J., Keith D.E. Jr., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science. 258(5090):1992;1952-1955.
27. Faden A.I. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. Jof Neuroscience. 12(2):1992;425-429.
28. Fan L., McIntosh T.K. Cardiovascular effects of microinjection of dynorphin fragments into the nucleus of the solitary tract (NTS) are mediated by non-opioid mechanisms. Brain Research. 623(1):1993;110-116.
29. Fang F., Fields H., Lee N.M. Action at the mu receptor is sufficient to explain analgesic action of opiates. Journal of Pharmacology and Experimental Therapeutics. 238(3):1986;1039-1044.
30. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological Review. 53(1):2001;1-24.
31. Fields H.L. Pain modulation: expectation, opioid analgesia and virtual pain. Progress in Brain Research. 122:2000;245-253.
32. Finn A.K., Whistler J.L. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 32(5):2001;829-839.
33. Friedman H.J., Jen M.F., Chang J.K., Lee N.M., Loh H.H. Dynorphin: a possible modulatory peptide on morphine or beta-endorphin analgesia in mouse. European Journal of Pharmacology. 69(3):1981;357-360.
34. George S.R., Fan T., Ibrahim M., Raffa B., Tallarida R.J., Malan T.P. Jr., Lai J., Porreca F. Oligomerization of m and d opioid receptors: generation of novel functional properties. Journal of Biological Chemistry. 275(46):2000;26128-26135.
35. Gintzler A.R., Pasternak G.W. Multiple mu receptors: evidence for mu2 sites in the guinea pig ileum. Neuroscience Letters. 39(1):1983;51-56.
36. Gomes, I., Jordan, B.A., Gupta, A., Trapaidze, N., Nagy, Y., Devi, L.A., 2000. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. Journal of Neuroscience 20 (22), RC110, 1-5.
37. Hazum E., Chang K.J., Cuatrecasas P. Opiate (Enkephalin) receptors of neuroblastoma cells: occurrence in clusters on the cell surface. Science. 206(4422):1979;1077-1079.
38. He L., Fong J., von Zastrow M., Whistler J.L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 108(2):2002;271-282.
39. He L., Lee N.M. DynorphinA(2-17) restores spinal/supraspinal morphine synergy in morphine-tolerant mice. Journal of Pharmacology and Experimental Therapeutics. 280(3):1997;1210-1214.
40. He L., Lee N.M. Delta receptor enhancement of mu-induced antinociception in spinal cord. Journal of Pharmacology and Experimental Therapeutics. 285(3):1998;1181-1186.
41. Hebert T.E., Moffett S., Morello J.P., Loisel T.P., Bichet D.G., Barret C., Bouvier M. A Peptide Derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. Journal of Biological Chemistry. 271(27):1996;16384-16392.
42. Herman B.H., Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin A. Journal of Pharmacology and Experimental Therapeutics. 232(1):1985;27-32.
43. Heyman J.S., Jiang Q., Rothman R.B., Mosberg H.I., Porreca F. Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. European Journal of Pharmacology. 169(1):1989;43-52.
44. Heyman J.S., Vaught J.L., Mosberg H.I., Haaseth R.C., Porreca F. Modulation of m-mediated antinociception by d agonists in the mouse: selective potentiation of morphine and normorphine by DPDPE. European Journal of Pharmacology. 165(1):1989;1-10.
45. Hollt V., Dum J., Blasig J., Schubert P., Herz A. Comparison of in vivo and in vitro Parameters of Opiate Receptor Binding in Naive and Tolerant/Dependent Rats. Life Sciences. 16(12):1975;1823-1828.
46. Horan P., Tallarida R.J., Haaseth R.C., Matsunaga T.O., Hruby V.J., Porreca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sciences. 50(20):1992;1535-1541.
47. Jiang Q., Takemori A.E., Sultana M., Portoghese P.S., Bowen W.D., Mosberg H.I., Porreca F. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 257(3):1991;1069-1075.
48. Jordan B.A., Cvejic S., Devi L.A. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 23(S4):2000;S5-S18.
49. Jordan B.A., Devi L.A. G-Protein coupled receptor heterodimerization modulates receptor function. Nature. 399(6737):1999;697-700.
50. Jordan B.A., Trapaidze N., Gomes I., Nivarthi R., Devi L.A. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proceedings of the National Academy of Sciences, U.S.A. 98(1):2001;343-348.
51. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The δ-Opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proceedings of the National Academy of Sciences, USA. 89(24):1992;12048-12052.
52. Kieffer B.L., Evans C.J. Opioid tolerance-in search of the holy grail. Cell. 108(5):2002;587-590.
53. Kishioka S., Morita N., Kitabata Y., Yamanishi T., Miyamoto Y., Ozaki M., Yamamoto H. Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance. Japanese Journal of Pharmacology. 60(3):1992;197-207.
54. Kong L.-Y., McMillian M.K., Hudson P.M., Jin L., Hong J.-S. Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. Journal of Pharmacology and Experimental Therapeutics. 280(1):1997;61-66.
55. Kovelowski C.J., Bian D., Hruby V.J., Lai J., Ossipov M.H., Porreca F. Selective opioid delta agonists elicit antinociceptive supraspinal/spinal synergy in the rat. Brain Research. 843(1-2):1999;12-17.
56. Kramer T.H., Shook J.E., Kazmierski W., Ayres E.A., Wire W.S., Hruby V.J., Burks T.F. Novel peptidic mu opioid antagonists: pharmacological characterization in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics. 249(2):1989;544-551.
57. Larson A.A., Vaught J.L., Takemori A.E. The potentiation of spinal analgesia by leucine enkephalin. European Journal of Pharmacology. 61(4):1980;381-383.
58. Law P.Y., Griffin M.T., Loh H.H. Mechanisms of multiple cellular adaptation processes in clonal cell lines during chronic opiate treatment. Mechanisms of Tolerance and Dependence NIDA Research Monograph. C.W. Sharp. vol. 54:1984;119-135 U.S. Government Printing Press, Washington, D.C.
59. Law P.Y., Wong Y.H., Loh H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annual Review of Pharmacology and Toxicology. 40:2001;389-430.
60. Lee N.M., Leybin L., Chang J.K., Loh H.H. Opiate and peptide interaction: effect of enkephalins on morphine analgesia. Journal of Pharmacology and Experimental Therapeutics. 68(2):1980;181-184.
61. Lefkowitz R.J., Pitcher J., Krueger K., Daaka Y. Mechanisms of beta-adrenergic receptor desensitization and resensitization. Advances in Pharmacology. 42:1998;416-420.
62. Levac B., O'Dowd B.F., George S.R. Oligomerization of opioid receptors: generation of novel signaling units. Current Opinion in Pharmacology. 2(1):2002;76-81.
63. Levine J.D., Gordon N.C. Synergism between the analgesic actions of morphine and pentazocine. Pain. 33(3):1988;369-372.
64. Lewis M.E., Khachaturian H., Watson S.J. Comparative distribution of opiate receptors and three opioid peptide neuronal systems in rhesus monkey central nervous system. Life Sciences. 33(Suppl. 1):1983;239-242.
65. Lord J.A.H., Waterfield A.A., Hughes J., Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 267(5611):1977;495-499.
66. Malmberg A.B., Yaksh T.L. Isobolographic and dose-response analyses of the interaction between mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB). Journal of Pharmacology and Experimental Therapeutics. 263(1):1992;264-275.
67. Marshall F.H. Heterodimerization of G-protein-coupled receptors in the CNS. Current Opinion in Pharmacology. 1(1):2001;40-44.
68. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics. 197(1):1976;517-532.
69. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., Denavit-Saubie M., Severini C., Negri L., Roques B.P., Maldonado R., Kieffer B.L. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. Journal of Neuroscience. 18(18):1998;7285-7295.
70. Mattia A., Vanderah T., Mosberg H.I., Porreca F. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 258(2):1991;583-587.
71. Mattia A., Farmer S.C., Takemori A.E., Sultana M., Portoghese P.S., Mosberg H.I., Bowen W.D., Porreca F. Spinal opioid delta antinociception in the mouse: mediation by a 5′-NTII-sensitive delta receptor subtype. Journal of Pharmacology and Experimental Therapeutics. 260(2):1992;518-525.
72. Mayer P., Schulzeck S., Kraus J., Zimprich A., Hollt V. Promoter region and alternatively spliced exons of the rat mu-opioid receptor gene. Journal of Neurochemistry. 66(6):1996;2272-2278.
73. McVey M., Ramsay D., Kellett E., Rees S., Wilson S., Pope A.J., Milligan G. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. Journal of Biological Chemistry. 276(17):2001;14092-14099.
74. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proceedings of the National Academy of Sciences, USA. 90(21):1993;9954-9958.
75. Milligan G. Oligomerisation of G-protein-coupled receptors. Journal of Cell Science. 114(7):2001;1265-1271.
76. Morre M., Bachy A., Gout B., Boigegrain R., Arnone M., Roncucci R. Kappa binding sites in guinea-pig brain membranes: evidence for a dynorphin-resistant subtype. Life Sciences. 33(Suppl. 1):1983;179-182.
77. Moskowitz A.S., Goodman R.R. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Research. 360(1-2):1985;117-129.
78. Ng G.Y., O'Dowd B.F., Lee S.P., Chung H.T., Brann M.R., Seeman P., George S.R. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochemical and Biophysical Research Communications. 227(1):1996;200-204.
79. Nimchinsky E.A., Hof P.R., Janssen W.G., Morrison J.H., Schmauss C. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. Journal of Biological Chemistry. 272(46):1997;29229-29237.
80. Pan Y.X., Xu J., Bolan E., Abbadie C., Chang E., Zuckerman A., Rossi G., Pasternak G.W. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Molecular Pharmacology. 56(2):1999;396-403.
81. Pan Y.X., Xu J., Mahurter L., Bolan E., Xu M., Pasternak G.W. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proceedings of the National Academy of Sciences, USA. 98(24):2001;4084-4089.
82. Pasternak G.W. High and low affinity opioid binding sites: relationship to mu and delta sites. Life Sciences. 31(12-13):1982;1303-1306.
83. Pavlovic Z.W., Bodnar R.J. Opioid supraspinal analgesic synergy between the amygdala and periaqueductal gray in rats. Brain Research. 779(1-2):1998;158-169.
84. Pfeiffer M., Koch T., Schroeder H., Laugsch M., Hollt V., Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization and desensitization. Journal of Biological Chemistry. 277(22):2002;19762-19772.
85. Pick C.W., Roques B., Gacel G., Pasternak G.W. Supraspinal m2-Opioid Receptors Mediate Spinal/Supraspinal Morphine Synergy. European Journal of Pharmacology. 220(2-3):1992;275-277.
86. Pollack G.H. Cells, Gels and the Engines of Life. 2001;Ebner and Sons, New York.
87. Porreca F., Heyman J.S., Mosberg H.I., Omnaas J.R., Vaught J.L. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of DPDPE in the mouse. Journal of Pharmacology and Experimental Therapeutics. 241(2):1987;393-400.
88. Porreca F., Jiang Q., Tallarida R.J. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. European Journal of Pharmacology. 179(3):1990;463-468.
89. Przewlocki R., Stala L., Greczek M., Shearman G.T., Przewlocka B., Herz A. Analgesic effects of mu-, delta- and kappa-opiate agonists and, in particular, dynorphin at the spinal level. Life Sciences. 33(Suppl. 1):1983;649-652.
90. Qi J.A., Mosberg H.I., Porreca F. Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective delta agonist in vivo. Life Sciences. 47(11):1990;PL43-PL47.
91. Quillan J.M., Sadee W. Dynorphin peptides: antagonists of melanocortin receptors. Pharmacological Research. 14(6):1997;713-719.
92. Quitterer U., Lohse M.J. Crosstalk between Galpha(i)- and Galpha(q)-coupled receptors is mediated by Gbetagamma exchange. Proceedings of the National Academy of Sciences, USA. 96(19):1999;10626-10631.
93. Rady J.J., Holmes B.B., Tseng L.F., Fujimoto J.M. Inverse agonist action of Leu-enkephalin at delta(2)-opioid receptors mediates spinal antianalgesia. Journal of Pharmacology and Experimental Therapeutics. 297(2):2001;582-589.
94. Ramarao P., Jablonski H.I. Jr., Rehder K.R., Bhargava H.N. Effect of kappa-opioid receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats. European Journal of Pharmacology. 156(2):1988;239-246.
95. Ramsay D., Kellett E., McVey M., Rees S., Milligan G. Homo- and hetero-oligomeric interactions between G protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer. Biochemical Journal. 365(Pt. 2):2002;429-440.
96. Riba P., Ben Y., Smith A.P., Furst S., Lee N.M. Morphine Tolerance in Spinal Cord is Due to Interaction Between μ- and δ-Receptors. Journal of Pharmacology and Experimental Therapeutics. 300(1):2002;265-272.
97. Roerig S.C. Decreased spinal morphine/clonidine antinociceptive synergism in morphine-tolerant mice. Life Sciences. 56(5):1995;PL115-PL122.
98. Roerig S.C., Fujimoto J.M. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. Journal of Pharmacology and Experimental Therapeutics. 249(3):1989;762-768.
99. Roerig S.C., Hoffman R.G., Takemori A.E., Wilcox G.L., Fujimoto J.M. Isobolographic analysis of analgesic interactions between intrathecally and intracerebroventricularly administered fentanyl, morphine, and d-ala2-d-leu5-enkephalin in morphine tolerant and non-tolerant mice. Journal of Pharmacology and Experimental Therapeutics. 257(3):1991;1091-1099.
100. Roerig S.C., O'Brien S.M., Fujimoto J.M., Wilcox G.L. Tolerance in morphine analgesia; decreased multiplicative interaction between spinal and supraspinal sites. Brain Research. 308(2):1984;360-363.
101. Romano C., Miller J.K., Hyrc K., Dikranian S., Mennerick S., Takeuchi Y., Goldberg M.P., O'Malley K.L. Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. Molecular Pharmacology. 59(1):2001;46-53.
102. Rossi G.C., Pan Y.X., Brown G.P., Pasternak G.W. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. Federation of European Biological Societies Letters. 369(2-3):1995;192-196.
103. Rossi G.C., Pasternak G.W., Bodnar R.J. Synergistic brainstem interactions for morphine analgesia. Brain Ressearch. 624(1-2):1993;171-180.
104. Rossi G.C., Pasternak G.W., Bodnar R.J. Mu and delta opioid synergy between the periaqueductal gray and the rostro-ventral medulla. Brain Research. 665(1):1994;85-93.
105. Rothman R.B., Westfall T.C. Allosteric coupling between morphine and enkephalin receptors in vitro. Molecular Pharmacology. 21(3):1982;548-557.
106. Rothman R.B., Westfall T.C. Morphine allosterically modulates the binding of [3H]leucine enkephalin to a particulate fraction of rat brain. Molecular Pharmacology. 21(3):1982;538-547.
107. Rothman R.B., Westfall T.C. Interaction of leucine enkephalin with (3H)naloxone binding in rat brain: evidence for an opioid receptor complex. Neurochemical Research. 8(7):1983;913-931.
108. Russell R.D., Leslie J.B., Su Y.F., Watkins W.D., Chang K.J. Interaction between highly selective mu and delta opioids in vivo at the rat spinal cord. NIDA Research. 75:1986;97-100.
109. Salim K., Fenton T., Bacha J., Urien-Rodriguez H., Bonnert T., Skynner H.A., Watts E., Kerby J., Heald A., Beer M., McAllister G., Guest P.C. Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. Journal of Biological Chemistry. 277(18):2002;15482-15485.
110. Satoh M., Minami M. Molecular pharmacology of the opioid receptors. Pharmacology and Therapeutics. 68(3):1995;343-364.
111. Schmauss C., Herz A. Intrathecally administered dynorphin-(1-17) modulates morphine-induced antinociception differently in morphine-naive and morphine-tolerant rats. European Journal of Pharmacology. 135(3):1987;429-431.
112. Schmidt B.L., Tambeli C.H., Levine J.D., Gear R.W. Mu/delta cooperativity and opposing kappa-opioid effects in nucleus-accumbens-mediated antinociception in the rat. European Journal of Neuroscience. 15(5):2002;861-868.
113. Selbie L.A., King N.V., Dickenson J.M., Hill S.J. Role of G-protein beta gamma subunits in the augmentation of P2Y2 (P2U)receptor-stimulated responses by neuropeptide Y Y1 Gi/o-coupled receptors. Biochemical Journal. 328(Pt. 1):1997;153-158.
114. Shah B.H., Siddiqui A., Qureshi K.A., Khan M., Rafi S., Ujan V.A., Yaqub Y., Rasheed H., Saeed S.A. Co-activation of Gi and Gq proteins exerts synergistic effect on human platelet aggregation through activation of phospholipase C and Ca2+ signalling pathways. Experimental and Molecular Medicine. 31(1):1999;42-46.
115. Shippenberg T.S., Rea W. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists. Pharmacology and Biochemistry of Behavior. 57(3):1997;449-455.
116. Shukla V.K., Lemaire S. Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides. Journal of Psychiatry and Neuroscience. 17(3):1992;106-119.
117. Sibley D.R., Benovic J.L., Caron M.G., Lefkowitz R.J. Molecular mechanisms of beta-adrenergic receptor desensitization. Advances in Experimental Medicine and Biology. 221:1987;253-273.
118. Smith A.P., Lee N.M. Pharmacology of dynorphin. Annual Review of Pharmacology and Toxicology. 28:1988;123-140.
119. Sofuoglu M., Portoghese P.S., Takemori A.E. Cross-tolerance studies in the spinal cord of beta-FNA-treated mice provides further evidence for delta opioid receptor subtypes. Life Sciences. 49(19):1991;Pl153-Pl156.
120. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 257(2):1991;676-680.
121. 5]enkephalin-induced analgesia. European Journal of Pharmacology. 324(2-3):1997;R1-R2.
122. Spampinato S., Candeletti S. Characterization of dynorphin A-induced antinociception at spinal level. European Journal of Pharmacology. 110(1):1985;21-39.
123. Specker S., Wananukul W., Hatsukami D., Nolin K., Hooke L., Kreek M.J., Pentel P.R. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology. 137(4):1998;326-332.
124. Stachura Z., Herman Z.S. The influence of the kappa agonist-spiradoline (U62066E) on the analgesic activity of some opioids at the spinal level. Polish Journal of Pharmacology. 46(1-2):1994;37-41.
125. Stafford K., Gomes A.B., Shen J., Yoburn B.C. mu-Opioid receptor downregulation contributes to tolerance in vivo. Pharmacology and Biochemistry of Behavior. 69(1-2):2001;233-237.
126. Stefano G.B., Hartman A., Bilfinger T.V., Magazine H.I., Liu Y., Casares F., Goligorsky M.S. Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. Journal of Biological Chemistry. 270(51):1995;30290-30293.
127. Sutters K.A., Miaskowski C., Taiwo Y.O., Levine J.D. Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids. Brain Research. 530(2):1990;290-294.
128. Suzuki T., Kishimoto Y., Ozaki S., Narita M. Mechanism of opioid dependence and interaction between opioid receptors. European Journal of Pain. 5(Suppl. A):2001;63-65.
129. Takemori A.E., Loh H.H., Lee N.M. Suppression by Dynorphin A-(1-13) of the Expression of Opiate Withdrawal and Tolerance in Mice. European Journal of Pharmacology. 221(2-3):1992;223-226.
130. Takemori A.E., Loh H.H., Lee N.M. Suppression by Dynorphin A and [Des-Tyr1]Dynorphin A Peptides of the Expression of Opiate Withdrawal and Tolerance in Morphine-Dependent Mice. Journal of Pharmacology and Experimental Therapeutics. 266(1):1993;121-124.
131. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain. 49(1):1992;93-97.
132. Tao P.L., Hwang C.L., Chen C.Y. U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs. European Journal of Pharmacology. 256(3):1994;281-286.
133. Tao P.L., Niu H.S., Lue W.M., Wang S.D. Immunohistochemical study of opioid receptors after chronic morphine treatment in rats. Proceedings of the National Science Council of the Republic of China B. 24(1):2000;14-19.
134. Taylor C.C., Wu D., Soong Y., Yee J.S., Szeto H.H. Dynorphin A1-13 stimulates ovine fetal pituitary-adrenal function through a novel nonopioid mechanism. Journal of Pharmacology and Experimental Therapeutics. 280(1):1997;416-421.
135. Thakker D.R., Standifer K.M. Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between mu and ORL1 receptors following prolonged agonist exposure. Neuropharmacology. 43(6):2002;979-990.
136. Tsushima H., Mori M., Matsuda T. Microinjection of dynorphin into the supraoptic and paraventricular nuclei produces antidiuretic effects through vasopressin release. Japanese Journal of Pharmacology. 63(4):1993;461-468.
137. Tulunay F.C., Jen M.F., Chang J.K., Loh H.H., Lee N.M. Possible regulatory role of dynorphin on morphine- and endorphin-dependent analgesia. Journal of Pharmacology and Experimental Therapeutics. 219(2-3):1981;296-298.
138. Vaught J.L., Takemori A.E. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. Journal of Pharmacology and Experimental Therapeutics. 208(1):1979;86-90.
139. Walker J.M., Tucker D.E., Coy D.H., Walker D.B., Akil H. Destyrosine dynorphin antagonizes morphine analgesia. European Journal of Pharmacology. 85(1):1982;121-122.
140. Wang F.S., Rady J.J., Fujimoto J.M. Elimination of the antianalgesic action of dynorphin A by spinal transsection in barbital-anesthetized mice. Journal of Pharmacology and Experimental Therapeutics. 268(2):1994;873-880.
141. Wen H.L., Ho W.K.K. Suppression of withdrawal symptoms by dynorphin in heroin addicts. European Journal of Pharmacology. 82(3-4):1982;183-186.
142. Whistler J.L., Chuang H.H., Chu P., Jan L.Y., von Zastrow M. Functional dissociation of μ opioid receptor signalling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron. 23(4):1999;737-746.
143. Whistler J.L., von Zastrow M. Morphine-activated opioid receptors elude desensitization by β-arrestin. Proceedings of the National Academy of Sciences, USA. 95(17):1998;9914-9919.
144. Wigdor S., Wilcox G.L. Central and systemic morphine-induced antinociception in mice: contribution of descending serotonergic and noradrenergic pathways. Journal of Pharmacology and Experimental Therapeutics. 242(1):1987;90-95.
145. Yeo A., Samwaya D.S., Fowler C.E., Gunn-Moore F., Henderson G. Coincident signalling between the Gi/Go-coupled delta-opioid receptor and the Gq-coupled m3 muscarinic receptor at the level of the intracellular free calcium in SH-SY5Y cells. Journal of Neurochemistry. 76(6):2002;1688-1700.
146. Yesilaltay A., Jenness D.D. Homo-oligomeric complexes of the yeast alpha-factor pheromone receptor are functional units of endocytosis. Molecular and Cell Biology. 11(9):2000;2873-2874.
147. Yeung J.C., Rudy T.A. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. Journal of Pharmacology and Experimental Therapeutics. 215(3):1980;633-642.
148. Yeung J.C., Rudy T.A. Sites of antinociceptive action of systemically injected morphine: involvement of supraspinal loci as revealed by intracerebroventricular injection of naloxone. Journal of Pharmacology and Experimental Therapeutics. 215(3):1980;626-632.
149. Yoburn B.C., Sierra V., Lutfy K. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation. Brain Research. 529(1-2):1990;143-148.
150. Zeng F.Y., Wess J. Identification and molecular characterization of m3 muscarinic receptor dimers. Journal of Biological Chemistry. 274(27):1999;19487-19497.
151. Zhu Y., King M.A., Schuller A.G., Nitsche J.F., Reidl M., Elde R.P., Unterwald E., Pasternak G.W., Pintar J.E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 24(1):1999;243-252.